QNTM (Quantum BioPharma) Cash And Cash Equivalents : $6.00 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Quantum BioPharma Cash And Cash Equivalents?

Quantum BioPharma's quarterly cash and cash equivalents declined from Jun. 2024 ($3.31 Mil) to Sep. 2024 ($3.12 Mil) but then increased from Sep. 2024 ($3.12 Mil) to Dec. 2024 ($6.00 Mil).

Quantum BioPharma's annual cash and cash equivalents declined from Dec. 2022 ($16.98 Mil) to Dec. 2023 ($2.76 Mil) but then increased from Dec. 2023 ($2.76 Mil) to Dec. 2024 ($6.00 Mil).

Quantum BioPharma Cash And Cash Equivalents Historical Data

The historical data trend for Quantum BioPharma's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quantum BioPharma Cash And Cash Equivalents Chart

Quantum BioPharma Annual Data

Trend

Aug15

Aug16

Aug17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

17.53

35.26

16.98

2.76

6.00

Quantum BioPharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial															2.76	1.33	3.31	3.12	6.00

Quantum BioPharma Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Quantum BioPharma (NAS:QNTM) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Quantum BioPharma Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Quantum BioPharma's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Quantum BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Quantum BioPharma Ltd (NAS:QNTM) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

0K91:Germany QNTM:Canada

Address

55 University Avenue, Suite 1003, Toronto, ON, CAN, M5J 2H7

Website

https://www.fsdpharma.com

Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.